Wall Street Journal has a new video on how Biogen’s Aduhelm is the first approved treatment for early-stage Alzheimer’s patients and that it may be able to slow the disease. WSJ explains how the drug interacts with brain cells, and why some doctors aren’t ready to prescribe it yet.